医疗保险受益者在抗癌药物上的支出:分析药物支出预测指标
Ashley Nee1, Alyson Haslam2, Vinay Prasad2
1Warren Alpert Medical School of Brown University, Providence, RI, United States.
Journal of cancer policy
|October 17, 2024
概括
医疗保险在新型癌症药物上的支出是由定价和患者人口规模决定的,而不是治疗价值. 为了补偿和癌症药物定价的透明度,需要进行改革.
科学领域:
- 在瘤学瘤学.
- 卫生经济学 卫生经济学
- 制药政策 制药政策
背景情况:
- 医疗保险对抗癌药物的支出大幅增加.
- 了解影响这些成本的因素对于医疗保健政策至关重要.
研究的目的:
- 评估与医疗保险在美国 (2012-2021) 新批准的抗癌药物方面的支出相关的因素.
主要方法:
- 美国FDA对瘤药物批准 (2012-2021) 的横截面分析.
- 对影响年度治疗费用的临床特征和机构因素的分析.
- 利用医疗保险和医疗补助服务中心的支出数据和FDA报告的药物因素.
主要成果:
- 97种新的抗癌药物符合研究标准,93%获得了FDA的加快指定.
- 在批准时对生存益处的数据有限 (40%的无进展生存率,19%的总生存率).
- 批准年与治疗人群大小相关;临床价值和价格之间没有发现联系.
结论:
- 医疗保险对抗癌药物的支出主要取决于参考价格和患者人口规模,而不是治疗价值.
- 在没有比较器的武器的情况下,倡导改革对药物的报销.
- 呼吁对接受这些治疗的患者提高透明度.
更多相关视频
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
14.4K
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
364
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Factors Influencing Drug Absorption: Disease States and Pharmacology
452
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
452
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
